Design, Synthesis, and Structure-Activity Relationship of N-Arylnaphthylamine Derivatives as Amyloid Aggregation Inhibitors

被引:26
作者
Di Santo, Roberto [1 ]
Costi, Roberta [1 ]
Crucitti, Giuliana Cuzzucoli [1 ]
Pescatori, Luca [1 ]
Rosi, Federica [1 ]
Scipione, Luigi [1 ]
Celona, Diana [2 ]
Vertechy, Mario [2 ]
Ghirardi, Orlando [2 ]
Piovesan, Paola [2 ]
Marzi, Mauro [2 ]
Caccia, Silvio [3 ]
Guiso, Giovanna [3 ]
Giorgi, Fabrizio [2 ]
Minetti, Patrizia [2 ]
机构
[1] Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, Dipartimento Chim & Tecnol Farmaco, I-00185 Rome, Italy
[2] Sigma Tau Pharmaceut Co, I-00040 Pomezia, Italy
[3] Ist Ric Farmacol Mario Negri, Dipartimento Neurosci, I-20156 Milan, Italy
关键词
ALZHEIMERS-DISEASE; ACCUMULATION; MECHANISM; BINDING; AGENTS; BRAIN; DRUGS;
D O I
10.1021/jm301105m
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Dyes like CR are able to inhibit the aggregation of A beta fibrils. Thus, a screening of a series of dyes including ABBB (1) was performed. Its main component 2 tested in an in vitro assay (i.e., ThT assay) showed good potency at inhibiting fibrils association. Congeners 4-9 have been designed and synthesized as inhibitors of A beta aggregation. A nurnber of these newly synthesized compounds have been found to be active in the ThT assay with IC50 of 1-57.4 mu M. The most potent compound of this series, 4k, showed micromolar activity in this test. Another potent derivative 4q (IC50 = 5.6 mu M) rapidly crossed the blood-brain barrier, achieving whole brain concentrations higher than in plasma. So 4q could be developed to find novel potent antiaggregating beta A agents useful in Alzheimer disease as well as other neurological diseases characterized by deposits of amyloid aggregates.
引用
收藏
页码:8538 / 8548
页数:11
相关论文
共 34 条
[1]  
[Anonymous], 2010, WORLD ALZEHIMER REPO
[2]   A study of rivastigmine liposomes for delivery into the brain through intranasal route [J].
Arumugam, Karthik ;
Subramanian, Ganesa Sundararajan ;
Mallayasamy, Surulivel Rajan ;
Averineni, Ranjith Kumar ;
Reddy, Meka Sreenivasa ;
Udupa, Nayanabhirama .
ACTA PHARMACEUTICA, 2008, 58 (03) :287-297
[3]   Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice [J].
Billings, LM ;
Oddo, S ;
Green, KN ;
McGaugh, JL ;
LaFerla, FM .
NEURON, 2005, 45 (05) :675-688
[4]   PHOTOSUBSTITUTION OF 1-METHOXY-4-NITRONAPHTHALENE WITH AMINE NUCLEOPHILES - DUAL PATHWAYS [J].
BUNCE, NJ ;
CATER, SR ;
SCAIANO, JC ;
JOHNSTON, LJ .
JOURNAL OF ORGANIC CHEMISTRY, 1987, 52 (19) :4214-4223
[5]  
Chen M, 1998, Front Biosci, V3, pA32
[6]   9,10-Anthraquinone hinders β-aggregation: How does a small molecule interfere with Aβ-peptide amyloid fibrillation? [J].
Convertino, Marino ;
Pellarin, Riccardo ;
Catto, Marco ;
Carotti, Angelo ;
Caflisch, Amedeo .
PROTEIN SCIENCE, 2009, 18 (04) :792-800
[7]   Immunotherapy for Alzheimer's disease [J].
Dodel, RC ;
Hampel, H ;
Du, YS .
LANCET NEUROLOGY, 2003, 2 (04) :215-220
[8]  
Frandrich M., 2007, CELL MOL LIFE SCI, V64, P2066
[9]   Alzheimer's Disease: From Pathogenesis to Disease-Modifying Approaches [J].
Galimberti, Daniela ;
Scarpini, Elio .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2011, 10 (02) :163-174
[10]  
Glabe CC, 2005, SUB CELL BIOCHEM, V38, P167